Protease Inhibitors in Development
April 4, 2011
These drugs have not been approved by the Food and Drug Administration (FDA) for use against HIV.
CTP-518 by GlaxoSmithKline is a new molecule that replaces some hydrogen molecules of atazanavir with deuterium, a related substance. Deuterium is metabolized more slowly than hydrogen. CTP-518 may maintain beneficial blood levels in humans without a booster. It is in Phase I trials.
TMC310911 by Tibotec Therapeutics is a new protease inhibitor in Phase II trials. It is boosted with ritonavir.
Brecanavir (GW640385) by GlaxoSmithKline and Vertex
L-756,423 by Merck
Mozenavir (DMP450) by Triangle Pharmaceuticals
PPL-100 (MK8122) by Ambrilla/Procyon Biopharma
RO033-4649 by Roche
SP1256 by Sequoia Pharmaceuticals
This article was provided by AIDS InfoNet. Visit AIDS InfoNet's website to find out more about their activities and publications.